rowinghippy

Get Ready to Hate Pharma Even More

2 posts in this topic

https://www.madinamerica.com/2016/12/real-mental-illness-epidemic-withdrawal-from-antidepressants/

 

"The FDA has just approved a drug to treat pseudobulbar affect. There is a push to declare pseudobulbar affect a common and often unrecognized condition. Pseudobulbar affect is a state where the patient’s mood is very labile, and they are easily moved to tears or laughter. It is an uncommon clinical finding...[but] is a very common symptom in patients who are withdrawing from SSRIs. Education courses are showing up, to teach the doctor to recognize what is described as a common and under diagnosed problem. So, when the patient who doesn’t realize that they are in withdrawal shows up with pseudobulbar affect, the psychiatrist is going to be able to make a diagnosis and prescribe another drug – anything as long as the withdrawal syndrome remains disguised as new illnesses."

 

At least we won't have to suffer from neuro-emotions anymore..

 

 

 

Side note, I'm assuming this is accurate, but I haven't researched it myself yet.

Share this post


Link to post
Share on other sites

i am not sure what drug he is referring to there.  i didnt find anything googling or using websites like http://www.centerwatch.com/drug-information/fda-approved-drugs/

 

however, i did see that "Nuedexta" (a combination of two drugs already in use) has been approved for pseudobulbar affect--a neuropsychiatric symptom generally resulting from a variety of neurological conditions.  it is made by combining the more familiar drugs dextromethorphan (aka DXM): https://en.wikipedia.org/wiki/Dextromethorphan and quinidine: https://en.wikipedia.org/wiki/Quinidine. you can read some writeups on the 2010 approval at places like http://www.medscape.com/viewarticle/731783 and http://mymsaa.org/news/nuedexta. perhaps he is referring to something else, like the newer MS drug "Zinbryta" which has similar uses to Nuedexta if he is not referring to Nuedexta itself.

 

i am in agreement with him, though--withdrawal syndromes are simply another way for pharmaceutical companies to make money.  ive stated previously on SA that i think they will market drugs for specific withdrawal symptoms, and that they will put off admitting to withdrawal being the precipitating element, but that once the cat is most fully and publicly 'out of the bag', they will push hard with self-acknowledging withdrawal 'treatments'.  this already happens to varying extents, with antidepressants for benzodiazepine withdrawal and vice versa, though prescribing psychiatric drugs for misdiagnosed withdrawal symptoms still far outpaces those kinds of attempts at amelioration.

 

that said, any drugs prescribed for pseudobulbar affect will generally be psychotropic in nature, meaning they will have many risks and 'side effects' in common with what people are already withdrawing from.  and when stray neurology drugs start getting prescribed by psychiatrists for allegedly psychiatric purposes, the potential for less familiar drug effects to emerge and be similarly misdiagnosed is heightened.  kaching.  ultimately, though, the non-falsifiability of psychiatry means any drugs can be useful and any diagnoses can be justified.  pharmaceutical companies navigate trends at least as often as they attempt to create them.

Share this post


Link to post
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!


Register a new account

Sign in

Already have an account? Sign in here.


Sign In Now